Table 1 Patients characteristics at baseline
Imaging Part | Therapeutic Part | ||||
|---|---|---|---|---|---|
N = 20 | N = 8 | ||||
N (%) | Arm A | Arm B | |||
N | N | ||||
Number of Patients | 20 | 3 | 5 | ||
Sex | |||||
Men | 10 (50.0%) | 2 | 3 | ||
Women | 10 (50.0%) | 1 | 2 | ||
Age at inclusion (years) | |||||
Mean | 42.1 | 31.0 | 41.4 | ||
SD | 13.68 | 10.44 | 13.59 | ||
Median | 43.0 | 26.0 | 43.0 | ||
Range | 21–67 | 24–43 | 21–57 | ||
PS (ECOG) | |||||
0 | 8 (40.0%) | 1 | 2 | ||
1 | 10 (50.0%) | 2 | 2 | ||
2 | 2 (10.0%) | 0 | 1 | ||
Primary tumor sites (at initial diagnosis) | |||||
Upper limb | 1 (5.0%) | 0 | 1 | ||
Lower limb | 8 (40.0%) | 2 | 2 | ||
Trunck wall | 5 (25.0%) | 0 | 2 | ||
Internal trunck | 4 (20.0%) | 0 | 0 | ||
Head and neck | 2 (10.0%) | 1 | 0 | ||
Histological type | |||||
Missing | 1 | 0 | 1 | ||
Spindle cell | 14 (73.7%) | 3 | 2 | ||
Biphasic | 2 (10.5%) | 0 | 1 | ||
Poorly differentiated | 3 (15.8%) | 0 | 1 | ||
Histological grade at initial diagnosis | Grade 2 | 7 (35.0%) | 3 | 2 | |
Grade 3 | 13 (65.0%) | 0 | 3 | ||
T | T1 | 5 (25.0%) | 0 | 2 | |
T2 | 14 (70.0%) | 3 | 3 | ||
TX | 1 (5.0%) | 0 | 0 | ||
N | N0 | 19 (95.0%) | 3 | 5 | |
N1 | 1 (5.0%) | 0 | 0 | ||
M | M0 | 20 (100%) | 3 | 5 | |
Tumor depth | |||||
Superficial | 3 (15.0%) | 1 | 2 | ||
Deep | 17 (85.0%) | 2 | 3 | ||
Disease status at inclusion | |||||
Metastatic | 18 (90.0%) | 3 | 4 | ||
Locally advanced | 1 (5.0%) | 0 | 1 | ||
Both | 1 (5.0%) | 0 | 0 | ||
Surgery of the primary tumor | |||||
Yes | 18 (90%) | 3 | 4 | ||
No | 2 (10%) | 0 | 1 | ||
Prior Radiotherapy | |||||
Yes | 15 (75.0%) | 3 | 3 | ||
No | 5 (25.0%) | 0 | 2 | ||
Chemotherapy with Doxorubicin | |||||
Yes, in monotherapy | 5 (25.0%) | 1 | 2 | ||
Yes, associated | 15 (75.0%) | 2 | 3 | ||
Chromosomal translocation site | |||||
missing | 1 | 0 | 0 | ||
SSX1 | 11 (57.9%) | 1 | 4 | ||
SSX2 | 5 (26.3%) | 1 | 0 | ||
Others | 3 (15.8%) | 1 | 1 | ||